Abstracts

Treatment of HIV-Infected Newborns: Why When and What to Start?

Background: Data have shown that early initiation of combination antiretroviral treatment (cART) in infants contributes to improved survival and neurodevelopmental, immunologic and growth outcomes. While cART cannot eradicate HIV infection in the majority of perinatally infected infants because of the long half-life of latently infected CD4 cells, time to achievement of viral suppression has been…

SAHA Dampens TCR-Mediated Reactivation of Latently Infected Cells

Background: Cell activation via T-cell receptor (TCR) stimulation represents a standard step in the analysis of primary cell models of HIV latency. Reactivation from latency using other pharmacological or immunological stimuli is generally benchmarked against the results of TCR signaling. We analyzed the molecular interaction between TCR stimulation and SAHA (a histone deacetylase inhibitor that…

HIV-1 Nef Inhibits Autophagy in Macrophages Through Transcription Factor EB Sequestration

Background: Transcription factor EB (TFEB) is a master gene expression regulator of the classical autophagy-lysosome pathway. Under basal conditions, TFEB is phosphorlyated by MTORC1, resulting in the cytoplasmic retention of TFEB through interactions with 14-3-3 proteins. When MTORC1 is inhibited, TFEB is dephosphorylated, prompting its translocation to the nucleus where it increases the expression of…

An In Vitro Compound Screen for Selective Apoptosis Induction In HIV-1 Infected Resting CD4+ T Cells

Background: Despite the ability of antiretroviral therapy to suppress viral replication, proviral HIV-1 persists in resting memory CD4+ T cells. These cells, termed the latent reservoir, represent a major barrier to HIV-1 eradication. One strategy to purge this reservoir, termed “shock and kill”, aims to induce proviral transcription without inducing cellular activation (the “shock”) with…

Failure of HIV-1 to Replicate in Human T Cells Expressing a Tat Mutant

Background: Our research indicates that Nullbasic[1] is possibly the strongest anti-HIV protein tested. Nullbasic inhibits HIV replication at 3 distinct steps of the viral life cycle: transcriptional activation by Tat, Rev-mediate RNA transport and HIV reverse transcription[1-3]. As Nullbasic opposes transactivation by Tat, a key step in the activation of latently infected T cells, we…

Hepatitis C Therapy Reduces CD4 T-Cell-Associated HIV-1 DNA in HIV-1/HCV Coinfected Patients

Background: Hepatitis C therapy with Interferon-α (IFN-α) and Ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for HIV-1 are unknown. This study aimed at elucidating the effects of combined therapy with IFN-α and Ribavirin against HIV-1 infected cells in HIV-1/HCV co-infected patients…

Panobinostat induces HIV transcription and plasma viremia in HIV patients on suppressive cART

Background: Reactivating HIV-transcription is currently investigated as a strategy to eliminate latently infected cells. We aimed to evaluate the ability of the potent histone deacetylase inhibitor (HDACi) panobinostat to reverse HIV latency. panobinostat to reverse HIV latency. Methodology: In a phase I/II clinical trial, HIV-infected adults received oral panobinostat 20 mg 3 times/week every other…

Ing-B a Potential PKC Activator for HIV Eradication is active in SIVmac251-infected macaques

Background: We here show the potential of a novel PKC activator, a hexanoate derivative of Ingenol (Ing-B) for purging the lentiviral reservoir in SIVmac251-infected macaques. cure. Here we present the preliminary results on a hexanoate derivative of Ingenol (Ing-B) in SIVmac251-infected macaques. Methodology: In a pilot trial in two SIVmac251-infected macaques, Ing-B was administered in…